Evercore ISI Group maintains Doximity at In-Line, lowers price target to $33 from $35
Evercore ISI Group kept Doximity's rating at In-Line but reduced its price target from $35 to $33, a 5.7% cut. The new target is close to Doximity's Nov 5 closing price of $33.18.
How this was made

The 30-second read
Why it matters
The downgrade may trigger modest sell‑offs, but the effect is limited given the small change and lack of broader catalyst.
Market read
A modest analyst target cut with limited immediate market impact; primarily relevant to traders with short positions in DOC.
What to watch
Potential upcoming product launches or partnership announcements that could offset the target reduction.
Background
Evercore ISI provides equity research coverage; price target adjustments are routine but can influence short‑term trading.
Market effects
Minimal impact on the broader health‑tech sector; only a single analyst view change.
U.S. market only; no regional ripple.
Low; Doximity is a niche professional network.
Counterpoint
Some investors may view the target cut as an overreaction and see buying opportunity if fundamentals remain solid.
Key entities
- Research FirmEvercore ISI Group
Equity research analyst firm issuing the target change.
- CompanyDoximity Inc.
Professional network for physicians, ticker DOC.



